PSTV

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.

Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 7.75 USD with a low forecast of 2.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Plus Therapeutics Inc revenue for the last quarter amounts to 1.40M USD, decreased -4.05 % YoY.

Plus Therapeutics Inc. EPS for the last quarter amounts to -0.04 USD, decreased -89.19 % YoY.

Plus Therapeutics Inc (PSTV) has 21 emplpoyees as of December 15 2025.

Today PSTV has the market capitalization of 93.97M USD.